Detection of Anthrax Toxin by an Ultrasensitive Immunoassay Using Europium Nanoparticles

Shixing Tang,1* Mahtab Moayeri,2 Zhaochun Chen,3 Harri Harma,4 Jiangqin Zhao,1 Haijing Hu,2 Robert H. Purcell,3 Stephen H. Leppla,2 and Indira K. Hewlett1*

Laboratory of Molecular Virology, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland 208921; Laboratory of Bacterial Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 208922; Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 208923; and Laboratory of Biophysics, University of Turku, Turku FIN-20520, Finland4

Received 10 November 2008/Returned for modification 8 December 2008/Accepted 17 December 2008

We developed a europium nanoparticle-based immunoassay (ENIA) for the sensitive detection of anthrax protective antigen (PA). The ENIA exhibited a linear dose-dependent pattern within the detection range of 0.01 to 100 ng/ml and was approximately 100-fold more sensitive than enzyme-linked immunosorbent assay (ELISA). False-positive results were not observed with serum samples from healthy adults, mouse plasma without PA, or plasma samples collected from mice injected with anthrax lethal factor or edema factor alone. For the detection of plasma samples spiked with PA, the detection sensitivities for ENIA and ELISA were 100% (11/11 samples) and 36.4% (4/11 samples), respectively. The assay exhibited a linear but qualitative correlation between the PA injected and the PA detected in murine blood (r = 0.97731; P < 0.0001). Anthrax PA was also detected in the circulation of mice infected with spores from a toxigenic Sterne-like strain of Bacillus anthracis, but only in the later stages of infection. These results indicate that the universal labeling technology based on europium nanoparticles and its application may provide a rapid and sensitive testing platform for clinical diagnosis and laboratory research.

Threats of bioterrorism have prompted renewed research interest in the development of rapid and sensitive assays for the detection of major CDC category A agents, such as Bacillus anthracis, which is of particular concern for bioterrorism, in light of the 2001 U.S. anthrax attack that led to 11 cases of inhalation anthrax and 5 deaths (10).

B. anthracis, the causative agent of anthrax, is a gram-positive bacterium that carries two virulence-related plasmids, pXO1 and pXO2 (32). The anthrax toxin is encoded by pXO1 and consists of three components: protective antigen (PA), lethal factor (LF), and edema factor (EF) (11). The PA component can rapidly bind to cellular receptors ANTXR1 or ANTXR2 and form a heptamer after the 83-kDa fragment. The PA heptamer subsequently combines with LF to form anthrax lethal toxin, which enters the cell through endocytosis and causes toxemia (1). Anthrax toxemia is the main cause of host system failure and death (17, 29). Most current approaches to anthrax therapy rely on antitoxin agents administered during the early stages of infection. Therefore, sensitive and rapid assays for the detection of B. anthracis toxin are urgently needed to facilitate an early and accurate diagnosis and successful treatment postexposure. Unfortunately, current enzyme-linked immunosorbent assays (ELISAs) for the detection of anthrax PA and LF are able to achieve sensitivity levels of only ~1 to 20 ng/ml (15, 18).

Over the past decade, nanotechnology-based techniques have been developed for use in medical testing and clinical diagnosis because of their high degrees of sensitivity and specificity and their ability to operate without enzymes (24). For example, gold nanoparticle (NP)-based bio-bar-code amplification (BCA) assays have been reported to be highly sensitive (19, 20, 28) and capable of detecting proteins such as prostate-specific antigen (PSA) at levels of as low as 30 aM (20) and human immunodeficiency virus type 1 p24 antigen at a lower limit of 0.1 pg/ml (28). However, the BCA assay involves multiple steps, including NP-based silver enhancement and a microarray detection method, and further simplification of the BCA technique would be needed to generate a simple, rapid assay system that could be applied in resource-poor settings. Our studies showed that a suitable replacement for gold NPs that can be used to simplify the detection method without having a significant impact on detection sensitivity is highly fluorescent europium (Eu3+) NPs. The use of Eu3+ NPs further permits the assay to be adapted to an ELISA format that is already in place in testing laboratories because the antibody-antigen sandwich complex bound to Eu3+ NPs coated with streptavidin (SA) can be directly measured with a fluorescence reader. Herein we report the development and evaluation of a Eu3+ NP-based immunoassay (ENIA) with a lower detection limit of 10 pg/ml for the sensitive detection of B. anthracis PA as a proof of concept for such a testing platform. This ultrasensitive NP-based assay for the detection of anthrax toxin could provide a useful new tool for clinical diagnosis and laboratory research.
ENHANCED DETECTION OF ANTHRAX TOXIN PA

MATERIALS AND METHODS

Samples. Control sera were obtained from healthy adults in a laboratory setting. BALB/cJ mice were injected intravenously (200 µl/mouse) with different amounts of wild-type PA, LF, or EF or premixed combinations of these toxins (all of which were prepared in phosphate-buffered saline [PBS]). In select experiments, an uncleavable PA mutant (PA-U7) which has been shown to have a slower rate of clearance from the circulation was utilized (18). At 2 or 6 h after injection, the mice were humanely killed, and the plasma was assessed for PA levels. In other experiments, plasma from untreated mice was spiked with known concentrations of PA. The plasma was assessed for PA levels. All experiments involving animals were performed under protocols approved by the Animal Care and Use Committee of the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH). It should be noted that all the samples were tested and coded in a blinded fashion.

Antigen, spore, antibody, and Eu⁺ NPs. Purified anthrax PA, LF, and EF proteins and rabbit anti-PA polyclonal antibody 5819 were prepared as described previously (18, 21, 30). Spores were prepared from the B. anthracis Ames 35 strain (22). This strain is a nontoxicogenic strain. The bacteria were grown on nutrient sporulation agar (25) at 37°C for 2 days to allow sporulation to occur. The spores were then removed from the plates by washing the plates with sterile water and were further purified by centrifugation through a gradient of Renograin (Bracco Diagnostics), as described previously (8).

Monoclonal anti-PA antibody W1 was isolated from a phage display library generated from immunized chimpanzees (4). This antibody was shown to bind to a conformational epitope formed by domain 4 (amino acids 614 to 735) of PA, which is responsible for cellular receptor binding (14, 31). The affinity (Kₐ) of W1 binding to PA was 4 × 10⁻¹¹ to 5 × 10⁻¹₁ mol/liter, which is 20- to 100-fold higher than the affinity of PA binding for the cellular receptor (4). Biotinylated goat anti-rabbit antibody was purchased from Pierce (Rockford, IL). Fluoro-Max polystyrene NPs (diameter, 107 nm) containing europium(III) [Eu⁺] diketone chelates and carboxyl groups on the surface for covalent bioconjugation were obtained from Seradyn Inc. (Indianapolis, IN). The preparation and the characteristics of Eu⁺ NPs were described previously (6). Each NP contains about 30,000 europium ions and approximately 700 SA molecules (5). The Eu⁺ NPs can produce intense long-lifetime fluorescent light identical to that observed with the dissociation-enhanced lanthanide fluorimunoassay (DELFIA) method (7).

ELISA for detection of PA. Fifty microliters of W1 (1.0 µg/ml) in 0.1 M phosphate buffer-0.15 M NaCl, pH 7.2 (coating solution), was incubated in Nunc Immuno Maxisorp strips (no. 437915; Fisher Scientific, Pittsburgh, PA) overnight at 4°C. The strips were then washed three times with 1× PBS-0.5% Tween 20 (PBS-T) in a DELFIA plate washer (Perkin-Elmer) and blocked with 300 µl of 1× PBS-1% casein (blocking buffer) at 37°C with shaking at 900 rpm for 1 h to remove unbound antibody and to ensure the blocking of nonspecific binding sites. For the assays, 100 µl of a series of purified PA dilutions in 1× PBS-0.25% Tween 20-0.5% casein (assay buffer) or appropriately diluted serum samples (initially diluted from 1:10) and appropriately diluted secondary rabbit anti-PA antibody were added to the strips, and the strips were incubated at 37°C with shaking at 900 rpm for 1 h. After the strips were washed five times with PBS-T, 100 µl of appropriately diluted biotinylated goat anti-rabbit antibody was added and the mixture was incubated for 30 min with shaking at 37°C. After the plate was washed with PBS-T, it was incubated with diluted peroxidase-SA conjugate (Pierce) for 30 min at room temperature and was stopped by the addition of 100 µl of 5 M H₂SO₄. The signal was then measured and quantified with a microtiter plate reader (Molecular Devices, Sunnyvale, CA). The cutoff value was established by using the sum of the means of the absorbance of six negative controls plus 3 standard deviations (SDs). Samples with signal-to-cutoff (S/CO) ratios equal to or greater than 1.0 were considered positive for anthrax PA.

RESULTS

Sensitivity of ELISA compared to results of ELISA for detection of anthrax PA. The ENIA scheme is depicted in Fig. 1. We adapted the immunosorbent assay format to capture target to form an antibody-antigen-antibody sandwich complex (steps 1 and 2). The immune complex is then coupled to SA-coated Eu⁺ NPs and Eu⁺ molecules through the biotin-SA interaction (step 3). After extensive washing between steps to remove unbound or nonspecifically bound conjugates, the fluorescence is measured with a fluorometer. The capture reagents that we used were purified monoclonal anti-PA antibody 14B7 and an engineered anti-PA single-chain variable fragment (scFv), W1. Both the 14B7 antibody and the engineered W1 scFv were shown to recognize an epitope in the receptor-binding domain of PA and to be able to bind to PA83 and PA63 in an ELISA and by Western blotting, although W1 shows a higher affinity than antibody 14B7 (4, 12, 13, 18). We found that W1 gave a slightly lower detection limit and a smaller variation than antibody 14B7, likely due to its higher affinity (data not shown). Therefore, the data presented here were derived by using W1 rather than 14B7.

Before subject samples were analyzed, we used ENIA and a conventional chromogenic in-house ELISA to establish calibration curves for the purified anthrax PA protein (Fig. 2). The ENIA exhibited an analytical target concentration range of 4 orders of magnitude (10 pg/ml to 100 ng/ml), with a lower limit of detection of 10 pg/ml. A good correlation between the anthrax PA concentration and the signal intensity (S/CO) was...
FIG. 2. Increased sensitivity of detection of anthrax PA of ENIA compared with that of an in-house ELISA. Purified anthrax PA at concentrations ranging from 1 pg/ml to 1 μg/ml in serial dilutions in PBS served as the targets. The normalized relative signal intensities are represented as the ratios of the samples over the cutoff value of the negative control (S/CO). Closed circles, results of ENIA; closed squares, results of ELISA. The error bars represent the standard deviations of at least three independent repeated experiments for each assay. The correlation (r value) between the S/CO ratios by the PA ENIA and the concentrations of anthrax PA was 0.9357 (R² = 0.8756; P < 0.0001).

TABLE 1. Detection of anthrax PA in mouse plasma spiked with different doses of PA, LF, and EF by ENIA and ELISA

| Panel and sample no. | Toxin concn spiked (ng/ml) | PA concn detected (ng/ml) |
|---------------------|---------------------------|--------------------------|
|                     | PA | LF | EF | ENIA | ELISA |
| Panel I             |    |    |    |      |       |
| 1                   | 100,000,000 |    |    | 27,000.00 | NDb |
| 9                   | 1,000,000  |    |    | 20.00   | ND  |
| 2                   | 400,000    |    |    | 425.00  | ND  |
| 4                   | 40,000     |    |    | 18.00   | ND  |
| 6                   | 4,000      |    |    | 3.30    | ND  |
| 3                   | 400        |    |    | 0.30    | ND  |
| 5                   | 40         |    |    | 0.00    | ND  |
| 7                   | 4         |    |    | 0.00    | ND  |
| 8                   | 0         |    |    | 0.00    | ND  |
| Panel II            |    |    |    |      |       |
| 5                   | 1,720.00  |    |    | 3,400.00 | 2,500.00 |
| 10                  | 172.00    |    |    | 125.00  | 37.00 |
| 24                  | 17.20     |    |    | 11.00   | 0.00 |
| 25                  | 1.72      |    |    | 0.60    | 0.00 |
| 28                  | 0.17      |    |    | 0.00    | 0.00 |
| 32                  | 0.02      |    |    | 0.00    | 0.00 |
| 47                  | 170.00    | 200.00 |    | 10.00   | 0.01 |
| 48                  | 1.70      | 2.00 |    | 1.50    | 0.00 |
| 54                  | 0.07      | 0.08 |    | 1.00    | 0.00 |
| 45                  | 170.00    | 165.00  |    | 41.00   | 0.01 |
| 46                  | 1.70      | 1.65 |    | 1.20    | 0.00 |
| 34                  | 2,000.00  |    |    | 0.00    | 0.00 |
| 39                  | 200.00    |    |    | 0.00    | 0.00 |
| 40                  | 20.00     |    |    | 0.00    | 0.00 |
| 19                  | 2.00      |    |    | 0.00    | 0.00 |
| 14                  | 0.20      |    |    | 0.00    | 0.00 |
| 4                   | 0.02      |    |    | 0.00    | 0.00 |
| 42                  | 1,650.00  |    |    | 0.00    | 0.00 |
| 43                  | 165.00    |    |    | 0.00    | 0.00 |
| 2                   | 0.16      |    |    | 0.00    | 0.00 |
| 53                  | 0.02      |    |    | 0.00    | 0.00 |

a Plasma from untreated mice was spiked with known concentrations of toxins and PA levels were assessed by two methods. The samples were diluted from 1:10 to 1:1,000.

b ND, not done.
The data are means ± SDs.

**TABLE 2. Detection of ENIA of PA in plasma from mice injected with different doses of toxin***

| Sample no. | PA dose injected (µg) | PA concn detected (µg/ml) |
|------------|-----------------------|---------------------------|
|            |                       |                           |
| 2          | 100                   | 26.80 ± 5.9               |
| 8          | 50                    | 19.00 ± 3.4               |
| 6          | 10                    | 1.60 ± 0.8                |
| 5          | 5                     | 0.24 ± 0.1                |
| 4          | 1                     | 0.08 ± 0.01               |
| 7          | 0                     | 0.00                      |

* Mice (n = 1 per dose) were injected with uncleavable PA (PA-U7) and were bled 2 h after injection. PA levels were then assessed by ENIA. The samples were diluted from 1:10 to 1:1,000.

The assay exhibited a linear, but qualitative, correlation between the PA assay exhibited a linear, but qualitative, correlation between the PA inhibited high concentrations of PA in their circulation. The mice injected with a range of doses (0 to 100 µg) (Table 2). It was apparent that the animals injected with high doses of PA exhibited high concentrations of PA in their circulation. The assay exhibited a linear, but qualitative, correlation between the PA injected and the PA detected in murine blood (r = 0.97731, P < 0.0001) (Prism software, version 4.0; GraphPad Software, Inc.). We next tested an additional 48 mouse plasma samples collected from two different experiments in which wild-type PA was injected into mice (Tables 3 and 4). Table 3 lists the results for the animals injected with 50 µg of PA, LF, or EF or 50 µg PA plus 50 µg LF. At 2 to 6 h after the injection, all 11 plasma samples from animals injected with PA or PA plus LF were still positive for PA, while another 12 samples collected from mice injected with LF or EF alone were PA negative. We also found that the PA concentration did not show a significant difference among animals injected with PA alone or with PA plus LF, although the PA concentration at 2 h after injection was slightly higher than that at 6 h after injection in both groups. It should be noted that the results obtained by ENIA and ELISA were highly similar. This finding was further confirmed by the data shown in Table 4. For the animals injected with 10 or 50 µg of PA and different amounts (5, 25, or 50 µg) of LF, the concentrations of PA detected in the blood were almost equal (0.81 to 1.09 µg/ml for mice receiving 10 µg of PA and 1.11 to 1.41 µg/ml for mice receiving 50 µg of PA). In addition, all seven animals injected with different doses of LF alone were PA negative. Our studies also confirmed the previous finding that uncleavable PA-U7 has a slower clearance rate than wild-type PA, as we found that the mouse injected with 50 µg of PA-U7 (Table 2, mouse 8) had dramatically higher levels of PA after 2 h than mice injected with same amount of wild-type PA (Tables 3 and 4) (18). These results further confirm the sensitivity and the specificity of our ENIA.

**TABLE 3. Detection of anthrax PA in mice injected with PA, LF, and EF**

| Toxin(s) | Bleeding time (h) | No. of animals | PA concn in blood (µg/ml) measured by: |
|----------|-------------------|---------------|---------------------------------------|
|          |                   |               | ENIA                                  |
| PA       | 2                 | 3             | 1.60 ± 0.40a                           |
| PA       | 6                 | 2             | 1.14 ± 1.51                            |
| PA + LF  | 2                 | 3             | 1.23 ± 0.15                            |
| PA + LF  | 6                 | 3             | 0.70 ± 0.10                            |
| LF       | 2                 | 3             | 0.00                                   |
| LF       | 6                 | 3             | 0.00                                   |
| EF       | 2                 | 3             | 0.00                                   |
| EF       | 6                 | 3             | 0.00                                   |

a BALB/cJ mice were injected intravenously (200 µl/vein) with 50 µg of wild-type PA, LF, or EF or with premixed combinations of these toxins (all prepared in PBS) and were bled 2 or 6 h after injection. The PA levels in plasma were assessed by the ENIA and ELISA methods. The samples were diluted from 1:10 to 1:1,000.

The samples were diluted from 1:10 to 1:1,000.

**TABLE 4. Detection of anthrax PA in mice injected with different doses of PA and LF by ENIA**

| Toxin dose injected (µg) | No. of animals | PA concn measured in blood (µg/ml) |
|--------------------------|---------------|-----------------------------------|
| PA                       |               |                                   |
| 50                       | 50            | 2                                |
| 50                       | 25            | 2                                |
| 50                       | 5             | 2                                |
| 10                       | 50            | 4                                |
| 10                       | 25            | 4                                |
| 10                       | 5             | 2                                |
| 10                       | 0             | 2                                |
| 0                        | 50            | 2                                |
| 0                        | 25            | 2                                |
| 0                        | 5             | 3                                |

α BALB/cJ mice (n = 2 to 4) were injected with different amounts of wild-type PA or LF or with premixed combinations of these toxins (all prepared in PBS) and were bled 2 h after injection. PA levels in plasma were assessed by ENIA. The samples were diluted from 1:10 to 1:1,000.

α The data are means ± SDs.

**TABLE 5. Detection of anthrax PA in mice infected with B. anthracis spores by ENIA**

| Dosage (no. of spores/mouse) | Bleeding time (h) | No. of animals | Illness grade | PA concn in blood (ng/ml) |
|------------------------------|-------------------|---------------|--------------|--------------------------|
| 107                          | 24–237            | 13            | –            | 0.00                     |
| 107                          | 6                 | 2             | –            | 0.00                     |
| 107                          | 8                 | 2             | –            | 0.00                     |
| 107                          | 24                | 2             | + + +        | 68 ± 75                  |
| 107                          | 42–48             | 2             | ++ +         | 408 ± 275                |
| 0                            | 24                | 2             | –            | 0.00                     |

α DBA/2J mice were exposed to different doses of B. anthracis spores and were bled at different times after infection. PA levels in plasma were assessed by ENIA. The samples were diluted from 1:10 to 1:1,000.

α Edema.

The data are means ± SDs.

**TABLE 6. Detection of anthrax PA in mice injected with different doses of PA and LF by ENIA**

| Toxin dose injected (µg) | No. of animals | PA concn measured in blood (µg/ml) |
|--------------------------|---------------|-----------------------------------|
| PA                       |               |                                   |
| 50                       | 50            | 2                                |
| 50                       | 25            | 2                                |
| 50                       | 5             | 2                                |
| 10                       | 50            | 4                                |
| 10                       | 25            | 4                                |
| 10                       | 5             | 2                                |
| 10                       | 0             | 2                                |
| 0                        | 50            | 2                                |
| 0                        | 25            | 2                                |
| 0                        | 5             | 3                                |

α BALB/cJ mice (n = 2 to 4) were injected with different amounts of wild-type PA or LF or with premixed combinations of these toxins (all prepared in PBS) and were bled 2 h after injection. PA levels in plasma were assessed by ENIA. The samples were diluted from 1:10 to 1:1,000.

α The data are means ± SDs.
current ENIA can detect PA in the circulation at later stages of infection with *B. anthracis*.

**DISCUSSION**

Sandwich ELISAs for the detection of anthrax PA with one monoclonal antibody and two polyclonal antibodies have been reported previously (15, 18). In these systems, the capture antibody was mouse monoclonal antibody M18 or 14B7. These antibodies have specificities similar to the specificity of monoclonal antibody W1 used in our study and are single-epitope capture reagents that target PA domain 4 (4, 12, 16). Interestingly, these assays, developed independently, were able to achieve the same lower detection limit of \(-1\) ng/ml for the purified PA protein (15, 18). However, when Eu\(^{3+}\) NPs were used to replace the traditional colorimetric development reagents in the conventional ELISA, the lower limit of detection was dramatically improved by almost 100-fold. Similar results have also been observed for the detection of the *B. anthracis* LF protein and the *Yersinia pestis* LcrV and F1 proteins, as well as human immunodeficiency virus type 1 p24 antigen (unpublished data). For example, our preliminary data indicate that the current assay conditions can detect 10 pg/ml of anthrax LF by using monoclonal anti-LF antibody and 20 ng/ml of anthrax EF by using PA63 as the capture reagent (data not shown). These results further support the importance of detection chemistries and new labeling technologies in improving assay performance and clearly indicate the potential of NP-based testing methods to enhance the sensitivity of immunoassays and to allow the ultrasensitive detection of pathogens.

Labeling technologies commonly used in immunoassays include radioactivity, enzyme activity, and chemicals (chemiluminescence and fluorescence). The use of radioisotopic labeling is being discontinued in many laboratories for several reasons, including the safety hazards that they pose. One major disadvantage of the enzyme-based colorimetric ELISA is its relatively low detection sensitivity. In the past decade, lanthanide chelates have successfully been used in immunoassays, such as the DELFIA technology. The DELFIA technology is based on the dissociation of lanthanide ions from chelates that target PA domain 4. The use of Eu\(^{3+}\) as a chelate in the DELFIA technology offers the advantage that it is 100-fold more sensitive than a similar assay that uses conventional Eu\(^{3+}\) NPs, especially SA-coated NPs, may be more useful than Eu\(^{3+}\) chelates in the development of assays with high amplification ratios and extremely high sensitivities.

In our study, we also used biotinylated anti-SA antibody and SA-coated Eu\(^{3+}\) chelates, followed by the addition of chelating enhancement solution to further enhance the signal intensity, since each NP contains more than 700 SA molecules and more than 2,800 biotin binding sites (5). We found that the enhancement step could further improve the signal intensity and could increase the sensitivity of the assay by twofold. The major advantage of our current assay format is that all the reagents are universal and can easily be adapted for the detection of different targets by replacing the coating and detection ligands. Furthermore, since the anti-PA IgG antibody is an important marker for the evaluation of anthrax vaccines, anti-PA assays with improved sensitivities would be useful in vaccine development and evaluation. Current assays are able to reach sensitivity limits of 1.5 to 3 pg/ml of anti-PA IgG antibody (2, 3, 23). We believe that the detection limits for the anti-PA IgG antibody could be further decreased by employing the ENIA. Although our current assay involves several incubation steps, it could be further developed as a two-step assay by using NP-antibody bioconjugate (25). The entire assay could be completed within 30 min. Therefore, the ENIA format could be suitable for rapid and point-of-care use.

As a proof-of-concept study, our preliminary results indicate that the ENIA described here has the potential to significantly improve the sensitivity of detection of anthrax toxin. The current ENIA also detected purified anthrax toxin and toxin-injected animal samples. The assay could also detect anthrax toxin after infection with *B. anthracis* spores, but only after the animals were sick and not at earlier stages of disease, before symptoms were apparent. Similar results have been reported by Mabry et al. (15). They used an engineered ELISA to measure the amounts of PA in blood samples from guinea pigs and rabbits exposed to a lethal dose of anthrax spores and found that PA could be detected only in the late stages of infection, especially within 12 h of death for the infected guinea pigs or 48 h for the infected rabbits (15). These findings are not surprising, as the anthrax toxin that is released into the circulation in the early stages of disease is likely to continuously bind to the available tissue receptors until receptor saturation is achieved. Only after saturation will the toxins accumulate in the blood and provide measurable levels in the blood, and the animals are usually sick by this stage.

More studies are needed to develop this nanotechnology-based testing method as a clinical diagnostic assay. Ideally, the early detection of the toxin in infected samples needs to be improved. Improvement of the sensitivity of the assay, coupled with knowledge of the kinetics of infection, may allow the detection of toxin in different sample types, such as infected tissues or cells which bind large amounts of toxin early in infection. In addition, to increase the sensitivity of detection of PA with mutations that may not be detectable with a single
monoclonal antibody, a polyclonal anti-PA antibody or a mixture of monoclonal anti-PA antibodies against different PA-reactive epitopes may be used. Due to the high specificity of SA-coated NPs, the high affinity between biotin and SA, and this universal labeling technique, the assay that we have developed may be suitable for the detection of biotinylated molecules and could be further developed as a rapid and universal testing platform for clinical diagnosis or laboratory research and for resource-limited settings upon further optimization and simplification.

ACKNOWLEDGMENTS

We acknowledge the Biodefense Advanced Research and Development Agency, DHHS, for funding and/or support. This work was also supported in part by the DIR, NIAID, NIH. We acknowledge Drusilla Burns, Krishna Devadas, and Hira Naikasri for review of the manuscript. We thank Devorah Crown and Sharmara Mayers for their invaluable help.

The findings and conclusions in this article have not been formally disseminated by the FDA and should not be construed to represent any agency determination or policy.

REFERENCES

1. Aboussi, L., M. Liu, P. Cosson, S. H. Leppla, and F. G. van der Goot. 2003. Anthrax toxin triggers endocytosis of its receptor via a lipid raft-mediated clathrin-dependent process. J. Cell Biol. 160:321–328.

2. Biagini, R. E., D. L. Sammons, J. P. Smith, B. A. MacKenzie, C. A. Striley, V. Semenova, E. Stewart-Clark, K. Stamey, A. E. Freeman, C. P. Quinn, and J. E. Snawder. 2004. Comparison of a multiplexed fluorescent isothermal microsphere immunoassay and an enzyme-linked immunosorbent assay for measurement of human immunoglobulin G antibodies to anthrax toxins. Clin. Diag. Lab. Immunol. 11:50–55.

3. Biagini, R. E., D. L. Sammons, J. P. Smith, B. A. MacKenzie, C. A. Striley, J. E. Snawder, S. A. Robertson, and C. P. Quinn. 2006. Rapid, sensitive, and specific lateral-flow immunochromatographic device to measure anti-anthrax protective antigen immunoglobulin G in serum and whole blood. Clin. Vaccine Immunol. 13:541–546.

4. Chen, Z., M. Moayeri, V. H. Zhou, S. Leppla, S. Emerson, A. Sehbell, F. Yu, J. Svitel, P. Schuck, M. St. Claire, and R. Purcell. 2006. Efficient neutralization of anthrax toxin by chimeric monoclonal antibodies against protective antigen. J. Infect. Dis. 196:625–633.

5. Harma, H., T. Soukka, T. Lovgren. 2003. Highly sensitive immunoassay of free prostate-specific antigen using europium(III) nanoparticle label technology. Clin. Chim. Acta 328:45–55.

6. Harma, H., T. Soukka, and T. Lovgren. 2001. Europium nanoparticles and time-resolved fluorescence for ultrasensitive detection of prostate-specific antigen. Clin. Chem. 47:561–568.

7. Hemmila, I., S. Dakubu, V. M. Mukkala, H. Siitari, and T. Lovgren. 2004. Comparison of a multiplexed fluorescent isothermal microsphere immunoassay and an enzyme-linked immunosorbent assay for measurement of human immunoglobulin G antibodies to anthrax toxins. Clin. Diag. Lab. Immunol. 11:50–55.

8. Biagini, R. E., D. L. Sammons, J. P. Smith, B. A. MacKenzie, C. A. Striley, J. E. Snawder, S. A. Robertson, and C. P. Quinn. 2006. Rapid, sensitive, and specific lateral-flow immunochromatographic device to measure anti-anthrax protective antigen immunoglobulin G in serum and whole blood. Clin. Vaccine Immunol. 13:541–546.

9. Chen, Z., M. Moayeri, V. H. Zhou, S. Leppla, S. Emerson, A. Sehbell, F. Yu, J. Svitel, P. Schuck, M. St. Claire, and R. Purcell. 2006. Efficient neutralization of anthrax toxin by chimeric monoclonal antibodies against protective antigen. J. Infect. Dis. 196:625–633.

10. Harma, H., T. Soukka, and T. Lovgren. 2001. Europium nanoparticles and time-resolved fluorescence for ultrasensitive detection of prostate-specific antigen. Clin. Chem. 47:561–568.

11. Hultin, P., T. Soukka, T. Lovgren, and H. Harma. 2004. Immunoassay of total prostate-specific antigen using europium(III) nanoparticle labels and streptavidin-biotin technology. J. Immunol. Methods 294:111–122.

12. Jernigan, J. A., D. S. Stephens, D. A. Ashford, C. Omenaca, M. S. Topiel, M. Galbraith, M. Tapper, T. L. Fisk, S. Zaki, T. Popovic, R. F. Meyer, C. P. Quinn, S. A. Harper, S. K. Fridkin, J. J. Sevajr, C. W. Shepard, M. Cottrell, J. Guarnier, W. J. Schieh, J. M. Malcke, J. L. Gerberding, J. M. Hughes, and P. A. Perkins. 2001. Bioterrorism-related inhalational anthrax; the first 10 cases reported in the United States. Emerg. Infect. Dis. 7:933–944.

13. Leppla, S. 2006. Bacillus anthracis toxins. p. 323–347. In J. E. Alouf and M. R. Popoff (ed.). The comprehensive sourcebook of bacterial protein toxins. Academic Press, Boston, MA.

14. Little, S. F., S. H. Leppla, and E. Cora. 1988. Production and characterization of monoclonal antibodies to the protective antigen component of Bacillus anthracis toxin. Infect. Immun. 56:1807–1813.

15. Littie, S. F., J. M. Novak, J. R. Lowe, S. H. Leppla, Y. Singh, K. R. Klippen, B. C. Lifdgerding, and A. M. Friedland. 1996. Characterization of lethal factor binding and cell receptor binding domains of protective antigen of Bacillus anthracis using monoclonal antibodies. Microbiology 142(Pt 3):707–715.

16. Liu, S., and S. H. Leppla. 2003. Cell surface tumor endothelium marker and inflammatory 8 cytotoxic tail-independent anthrax toxin binding, proteolytic processing, oligomer formation, and internalization. J. Biol. Chem. 278:5227–5234.

17. Mabry, R., K. Brasky, R. Geiger, R. Carriorn, J. B. Hubbard, S. Leppla, J. L. Patterson, G. Georgiou, and B. L. Isverson. 2006. Detection of anthrax toxin in the serum of animals infected with Bacillus anthracis by using engineered immunoassays. J. Clin. Microbiol. 44:416–422.

18. Mabry, R., M. Rani, R. Geiger, G. B. Hubbard, R. Carriorn, J. B. Brasky, J. L. Patterson, G. Georgiou, and B. L. Isverson. 2005. Passive protection against anthrax by using a high-affinity anthrax toxin antibody fragment lacking an Fc region. Infect. Immun. 73:1382–1388.

19. Moayeri, M., and C. A. Mirkin. 2005. Nanostructures in biodiagnostics. Chem. Rev. 105:1547–1562.

20. Schaffer, P., H. Ionesco, A. Ryter, and G. Balassa. 1963. Sporulation of Bacillus subtilis: genetic and physiological study. Colloq. Int. CNRS 124:553–563.

21. Soukka, T., T. K. Antonen, H. Harma, A. M. Pelikkanaksan, P. Huhtinen, and T. Lovgren. 2003. Highly sensitive immunoassay of free prostate-specific antigen in serum using europium(III) nanoparticle label technology. Clin. Chim. Acta 328:45–55.

22. Soukka, T., T. Paukkunen, H. Harma, S. Lonnenberg, H. Lindroos, and T. Lovgren. 2001. Supersensitive time-resolved immunofluorometric assay of free prostate-specific antigen with nanoparticle label technology. Clin. Chem. 47:1269–1278.

23. Tang, S., J. Zhao, J. J. Storhoff, P. J. Norris, R. F. Little, R. Yarchano, S. L. Stramer, T. Patno, M. Domansu, A. Dhar, C. A. Mirkin, and I. K. Hewlett. 2007. Nanoparticle-based biobarcode amplification assay (BCA) for sensitive and early detection of human immunodeficiency type 1 capsid (p24) antigen. J. Acquir. Immune. Defic. Syndr. 46:231–237.

24. Turk, B. E. 2007. Manipulation of host signalling pathways by anthrax toxins. Biochim. Biophys. Acta 176:405–417.

25. Varughese, M., A. Chi, A. V. Teixeira, P. J. Nichols, J. M. Keith, and S. H. Leppla. 1998. Internalization of a Bacillus anthracis protective antigen-c-Myc fusion protein mediated by cell surface anti-c-Myc antibodies. Mol. Med. 4:875–948.

26. Varughese, M., A. V. Teixeira, S. Liu, and S. H. Leppla. 1999. Identification of a receptor-binding region within domain 4 of the protective antigen component of anthrax toxin. Infect. Immun. 67:1860–1865.

27. Williamson, E. D., I. Hodgson, N. J. Walker, A. W. Topping, M. G. Duhars, J. M. Mott, J. Estep, C. Lebuet, H. C. Flick-Smith, H. E. Jones, H. Li, and C. P. Quinn. 2005. Immunogenicity of recombinant protective antigen and efficacy against aerosol challenge with anthrax. Infect. Immun. 73:5978–5987.